Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Trial Parameters
Brief Summary
This study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide as first-line treatment for extensive stage small cell lung cancer, and to observe the initial anti-tumor efficacy.
Eligibility Criteria
Inclusion Criteria: 1. Patients with extensive stage small cell lung cancer confirmed by histology or cytology; Has not received first-line systemic therapy or immune checkpoint inhibitor treatment for ES-SCLC in the past. 2. ECOG physical fitness score 0-1 points. 3. According to RECIST v1.1, there must be at least one measurable tumor lesion. 4. Expected survival time ≥ 12 weeks. 5. Having sufficient bone marrow and organ function. 6. Participants must give informed consent to this study prior to the trial and voluntarily sign a written informed consent form. Exclusion Criteria 1. Patients with central nervous system or meningeal metastases. 2. Spinal cord compression that cannot be cured by surgery and/or radiotherapy cannot be included in the study. 3. Patients diagnosed by researchers with uncontrollable tumor related pain. 4. Symptomatic third space effusion requires repeated drainage, such as pericardial effusion, pleural effusion, and abdominal effusion that cannot be controlle